{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:46:43Z","timestamp":1764510403390,"version":"build-2065373602"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.clml.2011.02.007","type":"journal-article","created":{"date-parts":[[2011,5,28]],"date-time":"2011-05-28T02:51:24Z","timestamp":1306551084000},"page":"S28-S36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S1","title":["JAK2 Inhibitors: Are They the Solution?"],"prefix":"10.1016","volume":"11","author":[{"given":"Fabio P.S.","family":"Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.02.007_bib1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.02.007_bib2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.02.007_bib3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.007_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2011.02.007_bib5","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib6","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAK2V617F-positive myeloproliferative disease","volume":"66","author":"Bumm","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.02.007_bib7","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib8","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2011.02.007_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F","volume":"22","author":"Shide","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.02.007_bib12","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib13","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib14","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice","volume":"111","author":"Xing","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib15","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F","volume":"1","author":"Zaleskas","year":"2006","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2011.02.007_bib16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib18","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.clml.2011.02.007_bib19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.007_bib20","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib21","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1073\/pnas.86.5.1603","article-title":"Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction","volume":"86","author":"Wilks","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2011.02.007_bib22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/protein\/15.9.727","article-title":"Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7","volume":"15","author":"Giordanetto","year":"2002","journal-title":"Protein Eng"},{"key":"10.1016\/j.clml.2011.02.007_bib23","first-page":"2057","article-title":"Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase","volume":"11","author":"Wilks","year":"1991","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clml.2011.02.007_bib24","doi-asserted-by":"crossref","first-page":"47954","DOI":"10.1074\/jbc.M205156200","article-title":"The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction","volume":"277","author":"Saharinen","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2011.02.007_bib25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.clml.2011.02.007_bib26","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1074\/jbc.274.9.5333","article-title":"Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils","volume":"274","author":"Al-Shami","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2011.02.007_bib27","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/blood-2002-07-2332","article-title":"Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation","volume":"101","author":"Bouscary","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1349-7006.2000.tb00977.x","article-title":"Ras and signal transducer and activator of transcription (STAT) are essential and sufficient downstream components of Janus kinases in cell proliferation","volume":"91","author":"Mizuguchi","year":"2000","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.clml.2011.02.007_bib29","doi-asserted-by":"crossref","first-page":"30837","DOI":"10.1074\/jbc.270.52.30837","article-title":"JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase\/mitogen-activated protein kinase by growth hormone","volume":"270","author":"Winston","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2011.02.007_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.clml.2011.02.007_bib31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.clml.2011.02.007_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/protein\/14.1.27","article-title":"Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation","volume":"14","author":"Lindauer","year":"2001","journal-title":"Protein Eng"},{"key":"10.1016\/j.clml.2011.02.007_bib33","doi-asserted-by":"crossref","first-page":"e11157","DOI":"10.1371\/journal.pone.0011157","article-title":"JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors","volume":"5","author":"Dusa","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2011.02.007_bib34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature08448","article-title":"JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin","volume":"461","author":"Dawson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.02.007_bib35","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/35065138","article-title":"Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain","volume":"410","author":"Bannister","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.02.007_bib36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/35065132","article-title":"Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins","volume":"410","author":"Lachner","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.02.007_bib37","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1182\/blood-2010-08-302265","article-title":"Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia","volume":"116","author":"Rinaldi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib38","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.02.007_bib40","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib41","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.02.007_bib42","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.02.007_bib43","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larran","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib44","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib45","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib46","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.02.007_bib47","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","article-title":"Anaemia characterises patients with myelofibrosis harbouring Mpl mutation","volume":"137","author":"Guglielmelli","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.02.007_bib48","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib49","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1172\/JCI42032","article-title":"Lnk constrains myeloproliferative diseases in mice","volume":"120","author":"Bersenev","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2011.02.007_bib50","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","article-title":"LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.02.007_bib51","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.755.755","article-title":"A Phase I evaluation of TG101348, a selective JAK2 Inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden [abstract]","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib52","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","article-title":"Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"115","author":"Santos","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib53","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of JAK1 & JAK2 inhibitor, INCB018424, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.02.007_bib54","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","article-title":"Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis","volume":"110","author":"Ciurea","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib55","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2003-12-4415","article-title":"IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis","volume":"105","author":"Emadi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0002-9440(10)64511-7","article-title":"Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity","volume":"157","author":"Lundberg","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2011.02.007_bib57","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1182\/blood.V96.4.1342","article-title":"Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis","volume":"96","author":"Schmitt","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib58","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2804.2804","article-title":"The clinical phenotype of myelofibrosis encompasses a chronic inflammatory state that is favorably altered by INCB018424, a selective inhibitor of JAK1\/2 [abstract]","volume":"112","author":"Tefferi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib59","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/sj.leu.2400846","article-title":"Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia","volume":"11","author":"Wang","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.02.007_bib60","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/blood-2008-09-176875","article-title":"Selective reduction of JAK2V617F-dependent cell growth by siRNA\/shRNA and its reversal by cytokines","volume":"114","author":"Jedidi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib61","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.leukres.2009.06.001","article-title":"How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis","volume":"33","author":"Vannucchi","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2011.02.007_bib62","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib63","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib64","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccr.2008.02.017","article-title":"Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors","volume":"13","author":"Geron","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2011.02.007_bib65","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2011.02.007_bib66","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1182\/blood-2007-04-083402","article-title":"Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2\/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders","volume":"111","author":"Hexner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib67","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.754.754","article-title":"A multicenter, open label phase I\/II study of CEP701 (lestaurtinib) in adults with myelofibrosis; a report on phase I: a study of the Myeloproliferative Disorders Research Consortium (MPD-RC) [abstract]","volume":"114","author":"Hexner","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib68","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.788.788","article-title":"Results From a randomized trial of salvage chemotherapy followed by lestaurtinib for FLT3 mutant AML patients in first relapse [abstract]","volume":"114","author":"Levis","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib69","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.538.538","article-title":"SB1518: A potent and orally active JAK2 inhibitor for the treatment of myeloproliferative disorders [abstract]","volume":"110","author":"Goh","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib70","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.3905.3905","article-title":"Phase I dose-escalation trial of SB1518, a novel JAK2\/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia\/polycythemia vera myelofibrosis [abstract]","volume":"114","author":"Verstovsek","year":"2009","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.clml.2011.02.007_bib71","article-title":"First Report of the rhase I study of the novel oral JAK2 inhibitor SB1518 in patients with myelofibrosis [abstract]","volume":"95","author":"Seymour","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.02.007_bib72","article-title":"A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera\/essential thrombocythemia myelofibrosis [abstract]","volume":"110","author":"Verstovsek","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib73","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.98.98","article-title":"A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis [abstract]","volume":"112","author":"Shah","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib74","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1016\/j.bmcl.2009.08.071","article-title":"Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)","volume":"19","author":"Burns","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.clml.2011.02.007_bib75","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","article-title":"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms","volume":"115","author":"Tyner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib76","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2009.50","article-title":"CYT387, a selective JAK1\/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients","volume":"23","author":"Pardanani","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.02.007_bib77","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccr.2009.10.015","article-title":"The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors","volume":"16","author":"Hedvat","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2011.02.007_bib78","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.311.311","article-title":"A phase 2 study of INCB018424, an oral, selective JAK1\/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea [abstract]","volume":"114","author":"Verstovsek","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib79","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.02.007_bib80","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.02.007_bib81","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.753.753","article-title":"An Open-Label Study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients [abstract]","volume":"114","author":"Moliterno","year":"2009","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:49Z","timestamp":1761870169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011000383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":81,"alternative-id":["S2152265011000383"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.02.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK2 Inhibitors: Are They the Solution?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}